T Cell News and Research

Latest T Cell News and Research

StemCells commences patient recruitment for a Phase I clinical trial of HuCNS-SC in PMD

StemCells, Inc. announced today that it has commenced patient recruitment for a Phase I clinical trial designed to test the safety and preliminary efficacy of its HuCNS-SC® purified human neural stem cells in Pelizaeus-Merzbacher Disease (PMD), a neurological disorder that primarily afflicts children. The study is being conducted at the University of California, San Francisco (UCSF) Children’s Hospital, one of the leading medical centers in the United States for neonatology, pediatric neurology and neurosurgery.

24 Nov 2009

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

Two recent FDA approvals have prompted the National Comprehensive Cancer Network (NCCN) to update the NCCN Clinical Practice Guidelines in Oncology(TM) for Non-Hodgkin's Lymphomas to include ofatumumab (Azerra(TM), GlaxoSmithKline) and romidepsin (Istodax(R), Gloucester Pharmaceuticals) as treatment options for select patients with two types of Non-Hodgkin's Lymphomas.

24 Nov 2009

BioAlliance Pharma's AMEP biotherapy reduces both tumour growth and tumour angiogenesis

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented preclinical results on its new biotherapy, AMEP™ for advanced and metastatic melanoma at the ESGCT (European Society of Gene and Cell Therapy) in Hannover (November 21 to 25, 2009).

24 Nov 2009

Studies examine interaction of ribosome with molecular partners

Two new studies reveal in unprecedented detail how the ribosome interacts with other molecules to assemble new proteins and guide them toward their destination in biological cells. The studies used molecular dynamics flexible fitting (MDFF) to examine the interaction of the ribosome with two prominent molecular partners.

24 Nov 2009

SANYO releases whitepaper on its new cell culture CO2 incubator

SANYO North America's Biomedical and Environmental Division has released a new whitepaper showing that higher up-time ratios, based on new protocols that minimize incubator downtime when compared to conventional decontamination methods, can accelerate a return on investment in cell culture CO2 incubators that use hydrogen peroxide vapor (H2O2) in conjunction with narrow-bandwidth ultraviolet light and copper-enriched stainless steel.

24 Nov 2009

Andor Technology reports 2009 preliminary results

ANDOR TECHNOLOGY PLC ("Andor") Preliminary Results for the year ended 30 September 2009 24 November 2009 Andor Technology plc (AND.L), the leading developer and manufacturer of high performance digital cameras and solutions for academic, industrial and government applications globally, today announces preliminary results for the year ended 30 September 2009.

24 Nov 2009

Scientists determine how insulin resistant drugs alter core biochemical pathways through systems biology approach

Researchers from the University of California, San Diego recently offered the sharpest-yet picture of how core biochemical pathways in skeletal muscle cells and fat cells are altered in people who suffer from insulin resistance-a primary defect in type 2 diabetes and obesity. Taking a systems biology approach, the bioengineers and medical researchers also determined how a common class of drugs for treating insulin resistance-TZDs-alter these same core pathways.

24 Nov 2009

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Clavis Pharma ASA, the clinical stage oncology focused pharmaceutical company, and Clovis Oncology, Inc., the newly formed oncology company led by former Pharmion Corporation executives, announced today an agreement for the further development and commercialisation of the Clavis Pharma drug candidate, CP-4126, currently in Phase II development in pancreatic cancer.

24 Nov 2009

Seattle Genetics and Agensys expand ADC collaboration

Seattle Genetics, Inc. (Nasdaq: SGEN) and Agensys, Inc., an affiliate of Astellas, announced today an expansion of the companies’ antibody-drug conjugate (ADC) collaboration. Under the amended agreement, Agensys will pay a $12 million fee for exclusive rights to ADC licenses against additional antigen targets. Seattle Genetics also receives an option to co-develop another ADC at the time of investigational new drug (IND) submission.

24 Nov 2009

NIGMS invests $42.3 million in "Grand Opportunities" grant

The National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH), is investing $42.3 million for grants in scientific areas it identified as "Grand Opportunities (GO)." NIH developed the GO grant program to stimulate biomedical research and the economy using funds provided by the American Recovery and Reinvestment Act (Recovery Act).

24 Nov 2009

PX’Therapeutics sets up additional biomanufacturing unit

PX’Therapeutics SA (formerly known as Protein’eXpert) announces the set up of an additional biomanufacturing unit dedicated to the production of therapeutic proteins and monoclonal antibodies in mammalian cells.

24 Nov 2009

Human-derived UCB stem cell transplant has positive therapeutic effects on specific lung and heart disorders

Two separate studies published in the current issue of Cell Transplantation (18:8), - now freely available on-line at http://www.ingentaconnect.com/content/cog/ct - have shown that transplanted human-derived umbilical cord blood (UCB) stem cells transplanted in an animal model had positive therapeutic effects on specific lung and heart disorders the animal models.

24 Nov 2009

New initiative launched to take care of patients with sickle cell disease

The Medical College of Georgia is leading an initiative that could result in a paradigm shift in the care of patients with sickle cell disease.

23 Nov 2009

C3a peptide regulates the generation of new nerve cells in the brain: Study

The generation of new nerve cells in the brain is regulated by a peptide known as C3a, which directly affects the stem cells' maturation into nerve cells and is also important for the migration of new nerve cells through the brain tissue, reveals new research from the Sahlgrenska Academy published in the journal Stem Cells.

23 Nov 2009

Lobbying is up as health industry examines impact of reform proposals

"Companies and groups hiring lobbying firms on health issues nearly doubled this year as special interests rushed to shape the massive revamp of the nation's health care system now in its final stretch before Congress." As many as 1,000 groups "have hired lobbyists since January, compared with 505 during the same period in 2008, according to a USA TODAY analysis of congressional records compiled by the nonpartisan CQ MoneyLine."

23 Nov 2009

Horizon Health International, Exmovere Holdings enter into a marketing and distribution agreement

HORIZON HEALTH INTERNATIONAL CORP. is pleased to announce that it has executed a Definitive Agreement with Exmovere Holdings Inc. of McLean, Virginia USA (Exmovere). Under the terms of the Agreement Horizon will pay Exmovere a total of two million dollars over a one year period for the exclusive rights to market and distribute their products in Canada for a 15 year term.

23 Nov 2009

Asterand extends its collaboration agreement with Bristol-Myers Squibb

Asterand plc, a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that it has extended its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to Asterand's products and services for up to three years.

23 Nov 2009

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, today announced positive interim results from a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) plinabulin (NPI-2358) in combination with standard chemotherapy (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC).

23 Nov 2009

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Human Genome Sciences, Inc. and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.

23 Nov 2009

Fred Hutchinson Cancer Research Center receives $10 million to advance biomedical research

Fred Hutchinson Cancer Research Center has received a pledge of $10 million to advance the promising field of immunotherapy research to treat and cure cancer, even in late stages.

23 Nov 2009

T Cell News and Research

Latest T Cell News and Research

StemCells commences patient recruitment for a Phase I clinical trial of HuCNS-SC in PMD

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

BioAlliance Pharma's AMEP biotherapy reduces both tumour growth and tumour angiogenesis

Studies examine interaction of ribosome with molecular partners

SANYO releases whitepaper on its new cell culture CO2 incubator

Andor Technology reports 2009 preliminary results

Scientists determine how insulin resistant drugs alter core biochemical pathways through systems biology approach

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Seattle Genetics and Agensys expand ADC collaboration

NIGMS invests $42.3 million in "Grand Opportunities" grant

PX’Therapeutics sets up additional biomanufacturing unit

Human-derived UCB stem cell transplant has positive therapeutic effects on specific lung and heart disorders

New initiative launched to take care of patients with sickle cell disease

C3a peptide regulates the generation of new nerve cells in the brain: Study

Lobbying is up as health industry examines impact of reform proposals

Horizon Health International, Exmovere Holdings enter into a marketing and distribution agreement

Asterand extends its collaboration agreement with Bristol-Myers Squibb

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Fred Hutchinson Cancer Research Center receives $10 million to advance biomedical research

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Newsletters you may be interested in